Head-to-Head: which JAK inhibitor tames rheumatoid arthritis best?
NCT ID NCT07636057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two drugs, tofacitinib and upadacitinib, added to standard methotrexate treatment for rheumatoid arthritis. One hundred adults in Pakistan will take one of the two drugs daily for six months. Researchers will measure disease activity and side effects to see which drug works better and is safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib and upadacitinib (JAK inhibitors) added to methotrexate
- What this could lead to
- If this trial succeeds, it could show which JAK inhibitor works better for rheumatoid arthritis in the Pakistani population, helping doctors choose the most effective treatment.
- What could go wrong
- This is a small, early-stage study with only 100 participants, so results may not apply to everyone. Both drugs have known risks like infections, and the trial hasn't started yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers